Aquestive Therapeutics (NASDAQ:AQST) CEO Daniel Barber Sells 25,000 Shares of Stock

Aquestive Therapeutics, Inc. (NASDAQ:AQST) CEO Daniel Barber sold 25,000 shares of Aquestive Therapeutics stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $4.82, for a total transaction of $120,500.00. Following the sale, the chief executive officer owned 652,317 shares of the company’s stock, valued at $3,144,167.94. The trade was a 3.69% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Aquestive Therapeutics Price Performance

Shares of NASDAQ:AQST traded down $0.04 during trading on Wednesday, reaching $4.77. 865,352 shares of the company were exchanged, compared to its average volume of 3,056,346. The business’s fifty day simple moving average is $4.41 and its 200-day simple moving average is $4.27. Aquestive Therapeutics, Inc. has a 12-month low of $2.93 and a 12-month high of $7.55. The firm has a market capitalization of $598.81 million, a PE ratio of -7.35 and a beta of 1.48.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.08). The company had revenue of $13.82 million during the quarter, compared to analysts’ expectations of $11.42 million. On average, sell-side analysts anticipate that Aquestive Therapeutics, Inc. will post -0.5 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on AQST shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $11.00 price objective on shares of Aquestive Therapeutics in a research note on Thursday, September 10th. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a report on Monday, August 24th. Wall Street Zen raised shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $9.17.

Institutional Investors Weigh In On Aquestive Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Bratton Capital Management L.P. acquired a new position in Aquestive Therapeutics during the 2nd quarter valued at about $40,813,585. BlackRock Inc. purchased a new stake in shares of Aquestive Therapeutics during the second quarter worth about $33,569,000. Bank of America Corp DE grew its stake in shares of Aquestive Therapeutics by 99.2% during the first quarter. Bank of America Corp DE now owns 2,405,050 shares of the company’s stock worth $9,981,000 after acquiring an additional 1,197,459 shares during the last quarter. Wasatch Advisors LP increased its holdings in shares of Aquestive Therapeutics by 57.8% during the second quarter. Wasatch Advisors LP now owns 1,385,843 shares of the company’s stock valued at $5,765,000 after acquiring an additional 507,527 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its position in shares of Aquestive Therapeutics by 6,233.4% in the 4th quarter. BNP Paribas Financial Markets now owns 1,171,675 shares of the company’s stock valued at $7,569,000 after purchasing an additional 1,153,175 shares during the last quarter. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines delivered through its PharmFilm technology. The company’s dissolvable oral-film platform is designed to provide alternatives to conventional tablets, capsules and injectable therapies, with potential benefits for patients who have difficulty swallowing or require rapid, convenient administration.

Aquestive’s commercial products include Exservan, an oral film formulation of riluzole for people with amyotrophic lateral sclerosis; Libervant, a buccal film formulation of diazepam for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity; and Sympazan, an oral film formulation of clonazepam for the treatment of seizures associated with Lennox-Gastaut syndrome.